Brief: Relief: U.S. Collaboration Partner Says FDA Declines Emergency Use Authorization For Aviptadil

MindMaze Therapeutics Holding SA

04/07/2022 06:06

July 4 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * RELIEF REPORTS THAT ITS U.S. COLLABORATION PARTNER HAS
ANNOUNCED
THAT THE FDA HAS DECLINED EMERGENCY USE AUTHORIZATION FOR
AVIPTADIL FOR A SUBGROUP OF PATIENTS WITH CRITICAL COVID-19 AT
IMMEDIATE RISK
    * THAT ITS U.S. COLLABORATION PARTNER HAS ANNOUNCED THAT FDA
HAS
DECLINED EMERGENCY USE AUTHORIZATION FOR AVIPTADIL FOR A
SUBGROUP OF PATIENTS WITH CRITICAL COVID-19 AT IMMEDIATE RISK OF
DEATH FROM RESPIRATORY FAILURE DESPITE TREATMENT WITH APPROVED
THERAPY, INCLUDING REMDESIVIR

Source text for Eikon:  ID:nEQ4r1KgTa 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))